Christopher J. Barden

Amministratore Delegato presso Treventis Corp.

Health Technology

Profilo

Christopher J.
Barden has held positions as the Chief Executive Officer at Treventis Corp.
and as the Chief Operating Officer & Director at DeNovaMed, Inc.

Posizioni attive di Christopher J. Barden

Società	Posizione	Inizio
Treventis Corp. Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada.	Amministratore Delegato	-
DeNovaMed, Inc. DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada.	Direttore operativo	-

Tutte le posizioni attive di Christopher J. Barden

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Christopher J. Barden

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Treventis Corp. Treventis Corp. BiotechnologyHealth Technology Treventis Corp. develops a small molecule drugs for Alzheimer's and other protein misfolding diseases. It developed a proprietary discovery platform, a high-resolution three-dimensional model of the common conformational region, enabling rational design of multiple lead compounds. The company was founded by Christopher J. Barden, Donald F. Weaver and Sultan Darvesh in 2008 and is headquartered in Toronto, Canada.	Health Technology
DeNovaMed, Inc. DeNovaMed, Inc. Pharmaceuticals: MajorHealth Technology DeNovaMed, Inc. develops an antibiotic to treat infections caused by drug-resistant bacteria or superbugs. It focuses in the areas of Gram-positive infections, methicillin-resistant Staph and vancomycin-resistant Enterococcus pose a threat to patients in hospitals and community health facilities by producing skin, wound and systemic infections. The firm also has an ongoing discovery program for Gram-negative adjuvants, which can improve the efficacy of older antibacterial. The company was founded by Donald F. Weaver, Christopher R. McMaster and David Byers in 2006 and is headquartered in Halifax, Canada.	Health Technology